INKON Life Technology Co., Ltd.

Equities

300143

CNE100000XF6

Healthcare Facilities & Services

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
7.88 CNY +1.68% Intraday chart for INKON Life Technology Co., Ltd. +4.37% -25.87%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
INKON Life Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on INKON Life Technology Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024. CI
INKON Life Technology Co., Ltd. announces an Equity Buyback for CNY 80 million worth of its shares. CI
INKON Life Technology Co., Ltd. authorizes a Buyback Plan. CI
INKON Life Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Inkon Life Technology Co., Ltd. Announces Directorate Appointments CI
INKON Life Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
INKON Life Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
INKON Life Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
INKON Life Technology to Set Up Medical Ecological Park for 566 Million Yuan MT
Qingdao Haiyingkang Investment Co., Ltd. and INKON Life Technology Co., Ltd. completed the acquisition of Shenzhen Shengzhong Investment Enterprise (Limited Partnership) from a group of shareholders. CI
Qingdao Haiyingkang Investment Co., Ltd. and INKON Life Technology Co., Ltd. agreed to acquire Shenzhen Shengzhong Investment Enterprise (Limited Partnership) from a group of shareholders for CNY 87.7 million. CI
INKON Life Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
INKON Life Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
INKON Life Technology Co., Ltd. announced that it expects to receive CNY 999.999998 million in funding from Qingdao Yingkang Medical Investment Co., Ltd. CI
INKON Life Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
INKON Life Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Tranche Update on INKON Life Technology Co., Ltd.'s Equity Buyback Plan announced on February 5, 2021. CI
INKON Life Technology Co., Ltd.'s Equity Buyback announced on February 5, 2021, has expired with 2,509,317 shares, representing 0.39% for CNY 50 million. CI
Tranche Update on INKON Life Technology Co., Ltd.'s Equity Buyback Plan announced on February 5, 2021. CI
INKON Life Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Tranche Update on INKON Life Technology Co., Ltd.'s Equity Buyback Plan announced on February 5, 2021. CI
INKON Life Technology Co., Ltd.(XSEC:300143) added to S&P Global BMI Index CI
Qingdao Yingkang Medical Investment Co., Ltd. acquired Hangzhou Yikang Traditional Chinese Medicine Tumor Hospital Co., Ltd. from INKON Life Technology Co., Ltd. for CNY 1.3 million. CI
INKON Life Technology : China cracks down on showbiz for 'polluting' society and youth RE
Chart INKON Life Technology Co., Ltd.
More charts
INKON Life Technology Co., Ltd., formerly Starmap medicine & technology Co., Ltd., is a China-based company principally engaged in providing medical services. Its medical services focus on cancer prevention, diagnosis, treatment and rehabilitation. The Company is also engaged in the research and development, manufacture and sales of medical equipment, as well as medical software development. Its medical equipment mainly include MASEP digital radiotherapy equipment, MASEP Gamma Knife and other large medical equipment. The Company distributes its products within domestic market and to overseas markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
7.88 CNY
Average target price
10.12 CNY
Spread / Average Target
+28.43%
Consensus

Annual profits - Rate of surprise